Nathan Pennell: Such an important statement to reduce administrative burden on research sites

Nathan Pennell, Professor and Vice Chair of Clinical Research at Cleveland Clinic, shared a post by American Society of Clinical Oncology on LinkedIn, adding:

“Such an important statement to reduce administrative burden on research sites! But it will only have impact if it leads to actual change, so I hope everyone especially the Food and Drug Administration (FDA) and pharma sponsors get on board to develop consensus guidelines on use the form 1572!”

Quoting American Society of Clinical Oncology’s post:

“A new American Society of Clinical Oncology (ASCO) research statement provides 4 recommendations to improve access to clinical trials through decentralization efforts. The first recommendation is for the Food and Drug Administration to clarify language that causes regulatory and administrative burden, while the other three are for the larger research community. Learn more on the Journal of Clinical Oncology.”

Additional information
Source: Nathan Pennell/LinkedIn and American Society of Clinical Oncology/LinkedIn